The cluster is entirely passive, no active manager signal. The selling by Morgan Stanley and UBS may reflect index rebalancing or risk-management adjustments, not a negative thesis. Monitor next 13F for active-manager entries or exits; the lack of activist/hedge-fund interest keeps the stock in a wait-and-see posture.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $29.96entry
- T+1 · 5mo ago +4.37%α +3.83% · $31.27
- T+5 · 5mo ago +9.91%α +9.48% · $32.93
- T+20 · 4mo ago +30.11%α +28.22% · $38.98
- T+60 · 2mo ago +30.57%α +26.75% · $39.12
How similar events traded
Executive Summary
A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesco) adding modest positions totaling $1.6M, while three mega-passive sellers (Morgan Stanley, UBS, T. Rowe Price) trimmed $11.8M in holdings. The net selling pressure of ~$10.2M from passive rebalancing is notable but lacks active-manager conviction, suggesting routine portfolio adjustments rather than a fundamental thesis.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$10.2M
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Wells Fargo | ADD | +56.6% | $1.8M | $872.0K |
| Invesco | ADD | +25.4% | $2.0M | $761.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -52.8% | $13.5M | -$5.4M |
| UBS | TRIM | -50.5% | $17.1M | -$6.3M |
| T. Rowe Price | TRIM | -37.6% | $78.0K | -$16.1K |
Key Facts
- 2 buyers added $1.6M in new holdings; 3 sellers reduced $11.8M
- All five institutions are mega-passive (index/quant), no active managers or hedge funds involved
- Largest seller: UBS trimmed $6.3M (-50.5% of position); Morgan Stanley cut $5.4M (-52.8%)
- Net aggregate change: -$10.2M, dominated by passive rebalancing
Financial Impact
Net institutional selling of approximately $10.2M, with total selling value of $11.8M versus buying of $1.6M
Risk Factors
- Passive selling could continue if CLDX is underweighted in indices
- No active-manager buying suggests limited catalyst-driven demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CLDX-2025-Q3 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers